Huisartsenbrochure myeloproliferatieve neoplasmata

13 / 15

Myeloproliferatieve neoplasmata
1. Babushok D, et al. Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Curr Opin
Hematol 2014;21:114–122.
2. Birgegård G, et al. Advances and challenges in the management of essential thrombocythemia. Ther Adv Hematol 2015;6:142–156.
3. Te Boekhorst P, et al. Richtlijn diagnostiek en behandeling van essentiële trombocytose, polycythaemia vera en primaire
myelofibrose. Ned Tijdschr Hematol 2011;8:64-79.
4. Emanuel R, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international
assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30:4098-4103.
5. Geyer H, et al. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm
2015;2015:284706.
6. Griesshammer M, et al. Current and future treatment options for polycythemia vera. Ann Hematol 2015;94:901–910.
7. Hendriks S. Generieke zorgthema Huisartsgeneeskundige zorg. 2014.
8. Hultcrantz M, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973
and 2005: a population-based study. JCO 2015;33:2288-2295.
9. Kröger N, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary
myelofibrosis. Blood 2015;125:3347-3350.
10. Mascarenhas J, et al. Advances in myelofibrosis: a clinical case approach. Haematol 2013;98:1499-1509.
11. Nederlandse Vereniging voor Hematologie. .
12. Nederlandse Vereniging voor Hematologie.
13. Nederlandse Vereniging voor Hematologie. .
14. Vajda I. Visiedocument Concentratie en organisatie van zorg bij zeldzame aandoeningen. 2015
Literatuurlijst
11